Free Trial

Exicure Q4 2023 Earnings Report

Exicure logo
$14.28 +2.96 (+26.15%)
As of 04:00 PM Eastern

Exicure EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Exicure Earnings Headlines

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
Exicure announces purchase agreement with GPCR Therapeutics
Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Exicure signs MOU with GPCR Therapeutics
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat